2016
DOI: 10.1016/j.biochi.2016.02.003
|View full text |Cite
|
Sign up to set email alerts
|

Pentoxifylline as a modulator of anticancer drug doxorubicin. Part II: Reduction of doxorubicin DNA binding and alleviation of its biological effects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
19
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 23 publications
(21 citation statements)
references
References 39 publications
2
19
0
Order By: Relevance
“…). In addition, potential protective effects of PTX towards DOX‐induced side‐effects have been reported, based on the capacity of PTX to sequester aromatic compounds (DOX) in staking complexes …”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…). In addition, potential protective effects of PTX towards DOX‐induced side‐effects have been reported, based on the capacity of PTX to sequester aromatic compounds (DOX) in staking complexes …”
Section: Discussionmentioning
confidence: 99%
“…a). High tumor cell density (tumor hyperplasia) may also create an interstitial barrier for penetration of drug molecules . Cell killing by GEM itself may therefore have augmented the reduction in solid stress, synergistically improving drug (GEM) delivery.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…DOX also interacts with the cell membrane and mitochondria, resulting in generation of reactive oxygen species leading to direct membrane damage and oxidative stress, responsible for the major DOX side effect, cardiomyopathy. [35,[40][41][42] DNA remains the main target of cancer therapeutics, whereby induction of DNA damage initiates a cascade of events that determines cellular apoptosis. DNA damage level and repair, by expression of anti-apoptotic proteins such as bcl-2 and resistance to apoptosis, are the main processes involved in carcinogenesis and in the response of cancer cells to cancer chemotherapy.…”
Section: B Drug Screeningmentioning
confidence: 99%